7.84
price up icon0.51%   0.04
after-market アフターアワーズ: 7.84
loading
前日終値:
$7.80
開ける:
$7.71
24時間の取引高:
2.60M
Relative Volume:
1.91
時価総額:
$866.02M
収益:
-
当期純損益:
$-227.05M
株価収益率:
-3.5636
EPS:
-2.2
ネットキャッシュフロー:
$-177.93M
1週間 パフォーマンス:
-3.80%
1か月 パフォーマンス:
-13.66%
6か月 パフォーマンス:
-6.22%
1年 パフォーマンス:
+51.94%
1日の値動き範囲:
Value
$7.68
$8.06
1週間の範囲:
Value
$7.295
$8.555
52週間の値動き範囲:
Value
$4.28
$12.61

Cogent Biosciences Inc Stock (COGT) Company Profile

Name
名前
Cogent Biosciences Inc
Name
セクター
Healthcare (1176)
Name
電話
617-945-5576
Name
住所
275 WYMAN STREET, WALTHAM
Name
職員
164
Name
Twitter
Name
次回の収益日
2024-10-31
Name
最新のSEC提出書
Name
COGT's Discussions on Twitter

COGT を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
COGT
Cogent Biosciences Inc
7.84 866.02M 0 -227.05M -177.93M -2.48
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
397.27 102.31B 10.63B -479.80M -1.35B -1.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
701.85 77.13B 13.85B 4.65B 3.32B 40.41
Biotechnology icon
ARGX
Argen X Se Adr
623.82 37.30B 1.86B -40.29M -1.28B -0.85
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
245.44 31.66B 2.09B -332.26M 16.06M -2.62
Biotechnology icon
BNTX
Biontech Se Adr
113.08 27.11B 3.30B -501.07M 1.03B -2.1146

Cogent Biosciences Inc Stock (COGT) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2024-12-11 ダウングレード Needham Buy → Hold
2024-02-26 ダウングレード Robert W. Baird Outperform → Neutral
2024-02-08 開始されました Citigroup Buy
2023-12-11 ダウングレード Wedbush Outperform → Neutral
2023-12-08 開始されました JP Morgan Overweight
2023-04-28 開始されました Robert W. Baird Outperform
2023-03-27 再開されました H.C. Wainwright Buy
2022-12-14 開始されました Needham Buy
2022-06-28 開始されました Guggenheim Buy
2021-10-11 開始されました H.C. Wainwright Buy
2021-06-09 再開されました Jefferies Buy
2020-12-23 開始されました Piper Sandler Overweight
2020-10-14 開始されました Ladenburg Thalmann Buy
すべてを表示

Cogent Biosciences Inc (COGT) 最新ニュース

pulisher
Dec 20, 2024

Cogent Biosciences, Inc. (NASDAQ:COGT) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat

Dec 20, 2024
pulisher
Dec 18, 2024

Cogent Biosciences (NASDAQ:COGT) Trading Down 4.4%What's Next? - MarketBeat

Dec 18, 2024
pulisher
Dec 18, 2024

Here's Why We're Watching Cogent Biosciences' (NASDAQ:COGT) Cash Burn Situation - Simply Wall St

Dec 18, 2024
pulisher
Dec 18, 2024

Cogent Biosciences, Inc. (NASDAQ:COGT) Stake Lowered by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC - Defense World

Dec 18, 2024
pulisher
Dec 16, 2024

Why Is Cogent Biosciences Stock Trading Higher On Monday? - AOL

Dec 16, 2024
pulisher
Dec 16, 2024

Cogent Biosciences, Inc. (NASDAQ:COGT) Sees Large Increase in Short Interest - MarketBeat

Dec 16, 2024
pulisher
Dec 14, 2024

What is HC Wainwright’s Forecast for COGT FY2024 Earnings? - Defense World

Dec 14, 2024
pulisher
Dec 14, 2024

HC Wainwright Issues Pessimistic Estimate for COGT Earnings - MarketBeat

Dec 14, 2024
pulisher
Dec 12, 2024

Needham Downgrades Cogent Biosciences (COGT) - MSN

Dec 12, 2024
pulisher
Dec 11, 2024

Cogent Biosciences (NASDAQ:COGT) Receives "Buy" Rating from HC Wainwright - MarketBeat

Dec 11, 2024
pulisher
Dec 11, 2024

Needham & Company LLC Downgrades Cogent Biosciences (NASDAQ:COGT) to Hold - MarketBeat

Dec 11, 2024
pulisher
Dec 11, 2024

Cogent Biosciences, Inc. (NASDAQ:COGT) Shares Purchased by Charles Schwab Investment Management Inc. - MarketBeat

Dec 11, 2024
pulisher
Dec 11, 2024

Charles Schwab Investment Management Inc. Has $8.92 Million Stock Holdings in Cogent Biosciences, Inc. (NASDAQ:COGT) - Defense World

Dec 11, 2024
pulisher
Dec 10, 2024

Cogent Biosciences (NASDAQ:COGT) Receives “Buy” Rating from Needham & Company LLC - Defense World

Dec 10, 2024
pulisher
Dec 09, 2024

Cogent Biosciences Announces Updated Clinical Results from Summit, Showcasing Powerful Symptomatic Improvement in NonAdvanced Systemic Mastocytosis Patients - Marketscreener.com

Dec 09, 2024
pulisher
Dec 09, 2024

Cogent Biosciences (NASDAQ:COGT) Given Buy Rating at Needham & Company LLC - MarketBeat

Dec 09, 2024
pulisher
Dec 09, 2024

Cogent Biosciences Announces Updated Clinical Results from - GlobeNewswire

Dec 09, 2024
pulisher
Dec 09, 2024

Cogent Biosciences Announces Updated Clinical Results from SUMMIT, Showcasing Powerful Symptomatic Improvement in NonAdvanced Systemic Mastocytosis Patients - Quantisnow

Dec 09, 2024
pulisher
Dec 08, 2024

Cogent Biosciences Announces Positive Updated Data from - GlobeNewswire

Dec 08, 2024
pulisher
Dec 08, 2024

Cogent's Bezuclastinib Shows Remarkable 83% Response Rate in Advanced Mastocytosis Trial - StockTitan

Dec 08, 2024
pulisher
Dec 08, 2024

(COGT) Pivots Trading Plans and Risk Controls - Stock Traders Daily

Dec 08, 2024
pulisher
Dec 06, 2024

Fmr LLC Has $89.85 Million Stake in Cogent Biosciences, Inc. (NASDAQ:COGT) - MarketBeat

Dec 06, 2024
pulisher
Dec 05, 2024

Cogent Biosciences, Inc. (NASDAQ:COGT) Stake Reduced by Redmile Group LLC - MarketBeat

Dec 05, 2024
pulisher
Dec 05, 2024

Bank of Montreal Can Takes $3.14 Million Position in Cogent Biosciences, Inc. (NASDAQ:COGT) - MarketBeat

Dec 05, 2024
pulisher
Dec 05, 2024

Intech Investment Management LLC Buys Shares of 28,424 Cogent Biosciences, Inc. (NASDAQ:COGT) - Defense World

Dec 05, 2024
pulisher
Dec 04, 2024

Why Is Cogent Biosciences, Inc. (COGT) Among the Best Small-Cap Biotech Stocks With Massive Potential According to Hedge Funds? - Insider Monkey

Dec 04, 2024
pulisher
Dec 03, 2024

Cogent Biosciences, Inc. (NASDAQ:COGT) Stake Lowered by HighVista Strategies LLC - MarketBeat

Dec 03, 2024
pulisher
Dec 03, 2024

Cinctive Capital Management LP Raises Stock Position in Cogent Biosciences, Inc. (NASDAQ:COGT) - MarketBeat

Dec 03, 2024
pulisher
Dec 01, 2024

COGT (Cogent Biosciences) Forward Dividend Yield % : 0.00% (As of Dec. 01, 2024) - GuruFocus.com

Dec 01, 2024
pulisher
Dec 01, 2024

Walleye Capital LLC Acquires Shares of 557,326 Cogent Biosciences, Inc. (NASDAQ:COGT) - MarketBeat

Dec 01, 2024
pulisher
Nov 30, 2024

Eventide Asset Management LLC Decreases Position in Cogent Biosciences, Inc. (NASDAQ:COGT) - MarketBeat

Nov 30, 2024
pulisher
Nov 28, 2024

Cogent Biosciences, Inc. (NASDAQ:COGT) Receives $14.83 Consensus PT from Brokerages - Defense World

Nov 28, 2024
pulisher
Nov 27, 2024

(COGT) Trading Advice - Stock Traders Daily

Nov 27, 2024
pulisher
Nov 25, 2024

Cogent Biosciences, Inc. (NASDAQ:COGT) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat

Nov 25, 2024
pulisher
Nov 18, 2024

Cogent Biosciences (NASDAQ:COGT) Price Target Raised to $21.00 at JPMorgan Chase & Co. - Defense World

Nov 18, 2024
pulisher
Nov 18, 2024

What is Leerink Partnrs' Estimate for COGT FY2024 Earnings? - MarketBeat

Nov 18, 2024
pulisher
Nov 18, 2024

FY2024 EPS Forecast for Cogent Biosciences Lifted by Analyst - Defense World

Nov 18, 2024
pulisher
Nov 16, 2024

Trend Tracker for (COGT) - Stock Traders Daily

Nov 16, 2024
pulisher
Nov 16, 2024

Cogent Biosciences (NASDAQ:COGT) Shares Down 7%Should You Sell? - MarketBeat

Nov 16, 2024
pulisher
Nov 16, 2024

Lifesci Capital Has Negative Outlook of COGT FY2024 Earnings - Defense World

Nov 16, 2024
pulisher
Nov 16, 2024

Equities Analysts Offer Predictions for COGT FY2024 Earnings - Defense World

Nov 16, 2024
pulisher
Nov 15, 2024

Leerink Partnrs Has Strong Forecast for COGT FY2027 Earnings - MarketBeat

Nov 15, 2024
pulisher
Nov 15, 2024

Wedbush Research Analysts Lower Earnings Estimates for COGT - MarketBeat

Nov 15, 2024
pulisher
Nov 15, 2024

FY2024 Earnings Estimate for COGT Issued By Lifesci Capital - MarketBeat

Nov 15, 2024
pulisher
Nov 15, 2024

COMMODORE CAPITAL LP's Strategic Acquisition in Cogent Biosciences Inc - GuruFocus.com

Nov 15, 2024
pulisher
Nov 14, 2024

Wedbush Reaffirms “Neutral” Rating for Cogent Biosciences (NASDAQ:COGT) - Defense World

Nov 14, 2024
pulisher
Nov 14, 2024

Kynam Capital Management, LP Reduces Stake in Cogent Biosciences Inc - GuruFocus.com

Nov 14, 2024
pulisher
Nov 13, 2024

Cogent Biosciences (NASDAQ:COGT) Announces Earnings Results, Misses Expectations By $0.07 EPS - MarketBeat

Nov 13, 2024
pulisher
Nov 13, 2024

Needham & Company LLC Cuts Cogent Biosciences (NASDAQ:COGT) Price Target to $15.00 - MarketBeat

Nov 13, 2024
pulisher
Nov 13, 2024

Cogent Biosciences Inc Reports Q3 2024 Net Loss Per Share of $0. - GuruFocus.com

Nov 13, 2024
pulisher
Nov 13, 2024

Cogent Biosciences Inc (COGT) Quarterly 10-Q Report - Quartz

Nov 13, 2024

Cogent Biosciences Inc (COGT) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$17.87
price down icon 2.88%
$68.84
price up icon 2.65%
$39.39
price down icon 0.43%
$359.58
price down icon 0.16%
$176.50
price up icon 1.02%
$113.08
price up icon 1.56%
大文字化:     |  ボリューム (24 時間):